Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Robert Proulx consultant service not in hiring announcement.
New Senior Scientific President and COO Robert R. Proulx has(had) a business development company called Turn The Crank (TTC). His relationship with Silicon Biosystems, Inc and others appear on the Current Work tab of this cached copy of TTC from Google dated Jan 13, 2015.
http://unix-mercenary.com/TTCAbout.html
Medical Tests: Sensitivity and Specificity
eatbytes, this Cancerquest link below describes sensitivity 'True Positives' and specificity 'True Negatives'.
http://www.cancerquest.org/medical-tests-sensitivity-specificity.html
Doubleclicking the large graphic on the page opens a short narrated video explaining sensitivity and specificity in medical testing.
Good to see MDAnderson poster from 2014 Seoul Imaging Conference touting Dr. Flynn's MRX device. Quote from the poster, "Because the technology relies on NPs (nanoparticles) binding to specific cancer cells and in detecting molecular markers, only cancer will presumably be detected with this technology", is a strong statement regarding the promise of MRX as earliest and most accurate screening possible for ovarian cancer in world today.
In this 'Pipeline company opens Wichita office" article, http://www.bizjournals.com/wichita/blog/2010/12/pipeline-company-opens-wichita-office.html from 2010, Randy Bruce, area manager for the TransCanada Keystone Pipeline said, “We try to position these offices out so throughout the region, the guys have a central place for records and storage and warehouse, to keep spare parts and equipment.”
Wichita is in Sedgwick County, Kansas. And the KeyStone Cushing line, on which TransCanada tested AOT, lies east of Sedgwich, moving through Cowley and Butler Counties Kansas before passing Wichita's latitude and proceeding nortward to Nebraska. Ponca City, Oklahoma, location of initial TCPL testing according to STWA filings, lies about 100 miles south of Wichita.
From the recent STWA 10Q period end 6/30/2014, STWA statement about Transcanada termination of AOT Lease-
On July 15, 2014, TransCanada notified the Company of TransCanada’s election to cancel, effective October 15, 2014. In exercising its termination right under the Lease, TransCanada stated “The justification for the early termination is due to the project working to expedite the required testing and believes the full term of the lease is unnecessary to successfully complete testing.” The lease continues to be effective through October 15, 2014, and testing of the Company’s equipment on TransCanada’s pipeline in Wichita, Kansas is ongoing. Data generated by, and results of the testing, have not yet been determined (See Note 8).
Any ideas how AOT may be 'ongoing' it's testing in TransCanadas admin/equipment yard in Wichita?
Productive discussions with TAL Oil and AWP Petro,
The Transalpine Pipeline (TAL) is a crude oil pipeline, which connects Italy, Austria and Germany. The pipeline starts from the marine terminal in Trieste*. From Trieste, the 465 kilometres (289 mi) long pipeline runs through the Alps to Ingolstadt. From Ingolstadt 21 kilometres (13 mi) long pipeline runs to Neustadt an der Donau and 266 kilometres (165 mi) long pipeline runs to Karlsruhe. In Vohburg, the Transalpine Pipeline is connected with the Ingolstadt-Kralupy-Litvínov pipeline, which supplies oil refineries in the Czech Republic. It could be used to reverse the southern branch of the Druzhba pipeline to supply Slovakia. In Würmlach, Austria, the Adria-Wien Pipeline (AWP) branches off from the Transalpine Pipeline. It supplies the OMV refinery in Schwechat. Through the proposed Bratislava - Schwechat Pipeline it may supply also Slovakia.
The diameter of the trunkline between Trieste and Ingolstadt is 40 inches (1,020 mm). Both sections starting from Ingolstadt are with 26 inches (660 mm) in diameter. The pipeline has ten pumping stations. The pipeline system includes tank farms in Trieste and Lenting, Germany. The capacity of the pipeline is approximately 43 million tons of crude oil per year. In 2012 the throughput of the pipeline was 34.9 million tons of crude oil.
TAL-IG (diameter 40”): connects the tank farm in San Dorligo della Valle (Trieste) with the tank farm in Lenting (Ingolstadt) and has a total length of 465 km and six intermediate pumping stations (three in Italy: Reana, Cavazzo and Paluzza, two in Austria: Kienburg and Gruben and one in Germany: Steinhöring)
TAL-NE (diameter: 26") a total lengh of 22 km connects the Gunvor refinery in Ingostadt and the tankfarm in Lenting with the Bayernoil refinery in Neustadt.
TAL-OR (diameter 26") a total length of 266 km and the three pumping stations (Ingolstadt, Ehringen and Hohenhaslach) connects the tankfarm in Lenting with the MiRO refinery in Karlsruhe. http://www.tal-oil.com/en/installations/transalpine-oelleitung.html
--------------------------------
The Adria–Wien Pipeline (AWP Petro) is a crude oil pipeline, which connects the Transalpine Pipeline from Würmlach at the Italian-Austrian border with the Schwechat Refinery near Vienna, Austria. It allows oil supplies to Austria from the Italian oil terminal in Trieste. The length of the pipeline is 420 kilometres (260 mi). It has also a 14 kilometres (8.7 mi) long branch line to Lannach. The diameter of the main pipeline is 18 inches (460 mm) and it consists of 12 pumping stations. The capacity of the pipeline is 8 million tons of crude oil per year. The pipeline is operated by Adria–Wien Pipeline GmbH, in which OMV owns 76%. Other shareholders are BP Austria, Shell Austria, Esso Austria and Agip http://www.adria-wien-pipeline.at/home.html?L=1
---------------------------------
*The Port of Trieste is a trade hub with a significant commercial shipping business, busy container and oil terminals, and steel works. The oil terminal feeds the Transalpine Pipeline which covers 40% of Germany's energy requirements (100% of the states of Bavaria and Baden-Württemberg), 90% of Austria and more than 30% of the Czech Republic's (wikipedia http://en.wikipedia.org/wiki/Trieste )
------------------------------------
Currently Transalpine transports oil offloaded from sea-going tanker at Trieste. A proposed Pan-European Pipeline, if constructed, will also supply the Transalpine Pipeline. The 2012 figures (2nd para above) show 81.2% Transalpine pipeline capacity utilization that year. AOT could be the most cost effective means for these two connected pipeline systems to handle any anticipated capacity challenge.
Good Pipeline reference for the interested, diameters, length, capacity, etc. World Pipelines maps http://www.theodora.com/pipelines/world_oil_gas_and_products_pipelines.html
Form 3 for STWA Independent Director Don Dicksn
Mr. Bigger said, "Management is currently exploring additional working capital resources" towards end of the recorded CC.
Don Dickson, CEO of Advanced Pipeline Services is liquidating the equipment of that company http://www.blackmonauctions.com/auctions/120/ in Sinton, TX beginning May 21, 2014
Don Dickson, Independent Director at STWA, said this of the $6.8 million Credit Facility obtained Dec 10, 2013 for Advanced Pipeline Services http://www.marketwatch.com/story/first-capital-provides-a-68-million-credit-facility-to-advanced-pipeline-services-llc-2013-12-10 "We were in need of a lender that could understand both our business and our industry," remarked Don Dickson, CEO of Advanced Pipeline Services. "First Capital was able to provide the additional working capital and flexibility we could not find through traditional lenders."
Looking over the equipment at auction, probably best suited for pipelaying to this layman's eyes. And AOT installations are delivered for aboveground co-install by pipeline operators and STWA.
Blowing through $6.8 million between Dec '13 and May '14, thoughts anyone? Maybe a Form 3(?) for Director Don Dickson soon?
Thx,Crunch55-n-DDHawk, Is this James Puthussery Application news?
Analyst withdraws Nanoco statement and management denies. Take a share price down for sure.
This 'Iron pyrite thin films from molecular inks' Application was published Jul 24, 2014. Excuse me if I missed it posted earlier.
https://www.google.com/patents/US20140205756?dq=James+Puthussery&hl=en&sa=X&ei=aVLcU93gEIfYoATay4DICQ&ved=0CBwQ6AEwAA
BigE had mentioned James Puthussery recently and I was trying to link him with Armand Paul Alivisatos. James Puthussery is co-inventor with Matt Law of UCIrvine on other nano-crystal patents.
Listening to Dr. Alivisatos mention nano-medicine probes and his funded research in his video, made me think of Tania Betancourts Star Park association with QTMM. Through long-lived-luminant tetrapod fluorophores for her now with QTMM, we may hear of similar work to these 2010 studies she was involved with.
This text is from a HHS SBIR 'circulating tumor cells (CTC) exploration' she was involved with in 2010:
lmmunonanoparticle Optical Sensor for CTC Detection,N43CO201000050,HHS,HHS,SBIR,2010,1,200000.00,"Innosense, LLC",2531 West 237th Street,,Torrace,CA,90505-5245,No,No,No,,,(310) 530-2011,kisholoy.goswami@innosense.us,Tania Betancourt,,,,"'Cancer remains one of the most prevalent diseases to date. Detection of circulating tumor cells (CTCs) in the vasculature has been identified as a promising method for determination of cancer risk, cancer prognosis, and determination of the effect of therapy. This proposal aims to establish the feasibility of a system for optical detection of CTCs that could be used in a point-of-care setting. Nanoparticles doped with near-infrared fluorophores and with high affinity to the cancer cells will be utilized for tagging CTCs in blood samples. The nanoparticles will provide high signal amplification for ultrasensitive detection. Phase I will focus on the evaluation of the diagnostic setup using body fluids spiked with CTCs. Phase II will develop a prototype and optimize the system for detection of patient samples. This project is expected to result in a small and rapid sensor that could be used at a physician's office or at small diagnostic laboratories, and which could become essential for the diagnosis and management of cancer patients."
Another HHS SBIR funded research from the same time period she was involved in investigated "long-circulating, targeted enzymatically-activated nanoparticles".
Enzyme-activated Nanoparticles as Contrast Agents for Optical Detection of Cancer,1R43CA144129-01,HHS,HHS,SBIR,2010,1,183896.00,"Innosense, LLC",2531 West 237th Street,,Torrace,CA,90505-5245,No,No,No,Kisholoy Goswami,,,kisholoy.goswami@innosense.us,Tania Betancourt,,3105302011,TANIA.BETANCOURT-1@INNOSENSE.US,"DESCRIPTION (provided by applicant): Despite great improvements in the detection of cancer in the last few decades, non-invasive early detection is still a challenge. Optical imaging is a modality that offers high spatio-temporal resolution, millimeters in depth of imaging, spectral resolution of tissue or contrast agent signals, and relative simplicity that would permit its use in real time at a physician's office or operating room. Despite these benefits, its application to the detection of developing tumors is limited due to the lack of optical contrast between normal and cancerous tissue. In the present proposal, InnoSense LLC aims to develop and perform preliminary in vitro and in vivo evaluation of injectable, long-circulating, targeted enzymatically-activated nanoparticles (EANPs) that act as cancer-specific contrast agents for non-invasive optical imaging of tumors. These nanoparticles, based on proven biocompatible and biodegradable polymers, will contain quenched near infra- red (NIR) fluorescent molecules that are activated upon interaction with target enzymes that are overexpressed in tumor tissue. The specificity of these nanoparticles to tumors will be increased by taking advantage of the enhanced permeability and retention effect that permits accumulation of nanoparticles at tumor tissue, and by the incorporation of antibodies specific to cancer biomarkers. The use of nanoparticles to improve the biodistribution and payload of the fluorescent molecules to tumors, combined with the cancer-specificenzyme-triggered development of NIR signal is expected to result in significantly increased signal-to-background levels in comparison to other contrast agent systems, thus improving the specificity and sensitivity of non-invasive optical detection. The biocompatibility and specificity of antibody- lacking and antibody-bound EANPs will be evaluated in vitro in normal and cancer cells. Optical contrast enhancement will be evaluated as a function of nanoparticle formulation, concentration and depth in tissue phantoms and in animal models of cancer. This project will be performed in collaboration with Dr. Bernard Choi, Assistant Professor of the Department of Biomedical Engineering and the Beckman Laser Institute of the University of California, Irvine. Upon completion of the Phase I feasibility study, a Phase II project will center on the optimization of EANP preparation, reproducibility, and scale up, and rigorous evaluation in animal models of cancer to determine optimal dose, NIR development time, and achievable imaging depth and spatial resolution.
PUBLIC HEALTH RELEVANCE: Despite great improvements in the detection of cancer in the last few decades, non-invasive early detection of tumors is still a challenge. Optical imaging is a modality that offershigh spatial and temporal resolution, the ability to detect and separate signals from tissue or contrast agents, millimeters in depth of imaging, and relative simplicity that would permit its use at a physician's office or operating room. Despite these benefits, its application to the detection of developing tumors is limited due to the low contrast between normal and cancerous tissue. In the present proposal, InnoSense LLC aims to develop and evaluate injectable, long-circulating, targeted enzymatically-activated nanoparticles (EANPs) that act as cancer-specific contrast agents for non-invasive optical imaging of tumors. EANPs, based on proven non-toxic polymers, will contain dormant fluorescent molecules that are activated upon interaction with enzyme molecules that are present in high levels in tumor tissue. The high payload of EANPs, together with their cancer-triggered activation will lead to high signal-to-background levels that improve the sensitivity of optical detection. This research will not only result in the development of a safe and effective option for non-invasive imaging of cancerous tissue, but will also further the body of scientific knowledge in the area of nanoparticle-based contrast agents and biomaterials."
dockzef - Alivisatos does have a lot to say.
Many irons in the fire with QTMM. Multiple paths for advancement.
crunch55, I'd looked at Nanoco website in the past after seeing them mentioned in some Display-related article. Just happened to see the DOW production plant headline in the right hand column of some webpage recently.
I dont know the particulars of that 'red ink' you mention, but their investors page today showed a 52 week high of 188 Poundds and trading now at 99 Pounds. By the dates given in their DOW licensing announcement, they'd about be qualifying their plant now. Dates pushed out is plenty common. Is there more to their 'red ink' than the slow start setting up production?
QTMM is 'ready to go' With Rice technology and Arizona 'roll to roll' QTMM is self-contained and no loose ends.
clearsudden, I'm no pro but I wish there were more un-issued shares (as a percentage of now outstanding) available for incentive/partnering possibilities.
Good weekend all, begin of month things to do.
Plant being built by Dow Chemical in South Korea
Jamis1, 25 March 2014 DOW-Nanoco (based in Britain) announced plant go-ahead
http://eandt.theiet.org/news/2014/mar/quantum-dot-tv.cfm
The one below is from Jan 2013 annoucing their global licensing agreement.
http://www.nanocotechnologies.com/media/press-releases/dow-sell-market-and-manufacture-cadmium-free-quantum-dots-lcd-displays
QTMM's reactor 'monthes ahead of schedule' so not to miss that train leaving the station imo.
Excuse my misquote BigE, seems I confuse 'running for the exits' in a downturn with some 'orchestrated dump so shorts profit handsomely' wherever I see pullbacks.
Thx for your price point Pecuniam. My >10,000 QTMM is my biggest holding since the run-up here, and like my SGLB, I watched it go up and fall back. I dont think this one will languish so long as SGLB. QTMM said there would be a few announcements before the second Tetrapod equipment is installed. That seems like progress here should happen (or not) in a shorter time frame than the 'further development and ongoing validation/testing SGLB has with GE and HON now'.
In the run-up I recognized some posters here from my A123 shame and SGLB experience, some serious penny-players if you will, urging others to buy the SP up. I believe BigE mentioned Canadian traders could short QTMM up there. Mr. Squires resolved an outstanding issue for investors in Canada, which, while understandable for QTMM at the time, belongs furthest in QTMM's past going forward.
Did you see the recent DOW Chemical announcement about QDot alliance for production? Validates the prospect of the space. QTMM has an exclusive means of production.
Paul Alivisatos -Berkley video discuss nanomaterials, nanomedicine, nanosensors
http://spie.org/x108554.xml?WT.mc_id=MSPIEPROGBW
Video link above Dr. Alivisato speaks directly about his labs nano-research and market potentials from 3:25 ~ 9:00
Here is Quantum Dot Solar Window Panels story dated 31 July 2014
http://genesisnanotech.wordpress.com/2014/07/31/quantum-dots-may-turn-house-windows-into-solar-panels/
This July 9 story is about FDA Final Guidance on Use of Nanotechnology in Regulated Products.
http://genesisnanotech.wordpress.com/tag/nano-drug-therapies/
The 5th story down the FDA Guidance page is a repost of a Virginia Tech NT News story by about QTMM securing their Anti-Counterfeiting technology from Virginia Tech's DREAM Lab.
The regulation standards probably necessitate Anti-Counterfeiting technolgy. Has anyone here looked into the FDA Guidance?
Sorry if any links are reposts.
Tetrapod nanocrystals make stronger polymers Pecuniam
This one is from Paul Alivisatos at Berkley. Talks of the 're-usability' stress sensors. Been seeing Dr. Alivisato frequently in links on this board and in my stumbling about the web.
http://phys.org/news/2013-07-tetrapod-nanocrystals-stronger-polymers.html
Are you shorting shares in Canada Pecuniam?
wooferwax, QDots last depending on purpose used for
I have read for luminesce in biological markers for cancer and disease screening, the 'game changer' in using QDots is they remain detectable in the body for up to 20 minutes, depending on use, compared to present technologies which fade sometimes in seconds to no more than a few minutes. That allows movement of tagged cells within a body to be followed a much longer time than current methods provide. And as a delivery method for treatments, more time to see its aggregation where needed.
For the stress sensors in composite material skins, tetrapods tested in the lab, are shown to be stressed to the breaking point of a material they would impregnate (thus indicating failure when in practicable such as in composite aerospace, structural, or transportation), thousands of times. And when the stress is removed, the tetrapods return to their original dimensions, having in effect the accuracy of a 'new' sensor again. One would surmise having such sensors to warn of a failure impending, would be used to bring a process to a halt pre-failure, or indicate a small part of broader area needing repair before the complete apparatus is returned to normal use.
And with solar, among the ways present panels are graded, includes a loss of efficiency over time brought on by age, average temperature operated at, etc. Depending on mfgr, panels will be sold claiming a certain efficiency remaining at 20 years for example. Such knowing of the solar devices lifetime is critical to let consumers evaluate a 'time for solar system ROI'. If some shortcoming meant QDot solar could not be made to last long enough to 'be worth its cost in practical use/benefit' compared to current market offerings, research would have dried up before now.
Maximizing the potential in individual market applications seems to be a period we are in now, with shipment for certain application already. The many NDA collaborations (with QTMM and others), as they arrive at sought results will lead to more market utilization. Not the best answer but maybe shows QDot longevity is wide and varied depending on app.
Advenira- Talks about next generation nano protective coatings
On the YouTube, Elmira Ryabova discusses thin-film photovoltaics(10:40), flat screens(12:00), even wanting to go public. John Heaton from QTMM announcement today speaks briefly at(3:40) and (15:16).
DDHawk, thankfully Elmira easier to understand than Klimov.
I had listened to Veeco Instruments (VECO) 2014 Q1 CC from May 5.
Analyst questions arose that anticipated OLED production equipment orders did not materialize as previous company guidance had indicated.
VECO management responded to analyst statement about Samsung impact abandoning OLED, and 'all but wrote off' expectation of any industry adoption of their 'recent R&D enhanced' FAST-ALD machine for OLED large-screen display purposes.
Flexible mobile display and OLED encapsulation were uses they hoped to sell their equipment into going forward
Although they are a trailing #3 by capitalization (according to Yahoo) of companys in that equipment making space, VECO's assessing disappeared possibility in large screen OLED indicates display industry changes QTMM is ready to participate in.
Let me echo 'great weekend all'.
santacruz -
Tania Betancourt, PhD is a researcher working with QTMM Tetrapods at Star Park. (Pictured here with Steven Squires and David Doderer) http://www.prnewswire.com/news-releases/unique-university---industry-partnership-to-spur-tetrapod-quantum-dot-commercialization-226107601.html
Her 2007 Dissertation, linked here,
http://books.google.com/books?id=qglb-G7LNm4C&pg=PR1&lpg=PR1&dq=%22Targetable+Biodegradable+Nanoparticles%22+%22Tania+Betancourt%22+dissertation&source=bl&ots=5TcY_SGbGx&sig=Et4fy9LswNRbhAAg4dmIVobKlYs&hl=en&sa=X&ei=U2i_U_XXLMP7oATa0YCoBw&ved=0CB0Q6AEwAA#v=onepage&q=%22Targetable%20Biodegradable%20Nanoparticles%22%20%22Tania%20Betancourt%22%20dissertation&f=false
is titled "Targetable Biodegradable Nanoparticles for Delivery of Chemotherapeutic and Imaging Agents to Ovarian Cancer" also describes her efforts to deliver Leukemia drug Doxorubicin via nanoparticles. I saw many links online about 2014 work for delivery of Doxorubicin via QDs.
I happened on this readable tutor also, "Designing multifunctional quantum dots for bioimaging, detection, and drug delivery" http://faculty.washington.edu/xgao/Images/Pavel2010Review.pdf
Imaging of treatment of cancer using QDs looks promising.
IEE/CEEM Seminar Video- Solution Processed QDs for Solar Lighting
Dr Vanessa Wood heads Laboratory for Nanoelectronics at ETH Zurich, gives seminar, http://vimeo.com/89144871 Audio begins at 3:10. Alloyed QDs and Giant Shell QDs are compared, (warning -feedback squeal 3:40-3:42). Topic changes to electrochemistry battery tortuousity at 27:10. QDot question are answered 50:45-54:26 and 57:30-out.
lineman68 posted about Roy Martin Board Member. This link, http://www.thefreelibrary.com/Asyst+Technologies+Inc.+recruits+Ray+Martin+as+its+new+director+of...-a016600709 about his recruitment to Asyst Technologies describes expertise good for QTMM scale-up.
Maybe somebody could help me see those 10 patents of Ray Martin mentioned different places. This May 2012 link, http://www.prweb.com/releases/ALT/LEDdriver/prweb9468478.htm is about Martin's ALT, Inc. Introducing patented High-Efficiency Monolithic LED Driver Technology. The 'system on a chip' for lighting may fit into QTMM future.
Ray Martin also is involved with Sustainable Silicon Valley, http://www.sustainablesv.org/ssv2013/index.php/about-us/ssv-board-and-advisory-council and with the International Technology Roadmap for Semiconductors http://www.itrs.net/
$50k MDAnderson Sprint Awardee detect ovarian via nanomagnetic-relaxometry
Early detection ovarian cancer through nanomagnetic relaxometry (This first link includes a date, 6/6/1014, assumably of the award)
http://explore.mdanderson.org/search?site=my_collection&client=my_collection&output=xml_no_dtd&proxystylesheet=my_collection&q=nanomagnetic
(The second link gives Sprint for Life awardees for past 12 years including this 2014 award for Early detection ovarian cancer through nanomagnetic relaxometry. Links for named Awardee researchers other years either link to 'blank|nothing' or to their own extended bio's. No in-depth of the awards or outcomes unfortunately)
http://www.mdanderson.org/how-you-can-help/other-ways-to-help/sprint-for-life/donate/awardees.html
(And third link here is PhD Kelsey B Mathieu, named as Awardee in the MDAnderson 'People Finder'.)
https://www2.mdanderson.org/app/peoplefinder/person.cfm?id=3D59D9DCC119
DDhawk, yes I'd watched Hollingsworth's 80 minute video before.
In the "Behind the White Coat" video,
J.Hollingsworth complete April 2013 thick-shell research manuscript
Here is Jennifer Hollingsworth's April 2013 complete author manuscript titled, "Heterostructuring Nanocrystal Quantum Dots Toward Intentional Suppression of Blinking and Auger Recombination"
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778929/
She writes, "In the context of NQD (Nanocrystal Quantum Dots) lasing applications, AR (Auger Recombination) severely limits the lifetime and bandwidth of optical gain, while in the case of NQD photovoltaics, AR restricts the available time to extract multiple excitons generated via carrier multiplication. For these reasons, in addition to its role in blinking, remedies for efficient AR are technologically significant."
In the conclusion, "Three approaches to NQD heterostructuring that enable suppression of blinking and AR have been reviewed here: (1) interfacial alloying, (2) thick or “giant” shells, and (3) specific type-II electronic structures. Each has been applied with the intention to control or eliminate non-radiative processes that otherwise hinder application of NQDs for a range of uses from single-particle tracking and advanced bioimaging to lasing, single-photon light sources and solid-state lighting. As a result of these recent studies, structural motifs are beginning to emerge as design criteria for realizing non-blinking and dramatically suppressed AR functionality."
How much can shipping be for nanoparticles anyways?
Specvestor thx for the links
"... there is a requirement for substantial manufacturing of licensed products and methods within the U.S"
Question about Thick-Shell Patent, Feb'14 Hollingsworth video
DDhawk, I wasn't certain the Hollingsworth-Mikhailovski Award was fresh news. When I finally found a cached version of the "Hollingsworth constructs Quantum Dot and nanowires" article you posted , then I was certain they were different. They were both from April 2014. Yes, there is just one Jennifer Hollingsworth at LANL as you and chessmite say. And you are right about Hollingsworth, Mikhailovski, and Klimov going way back. I'm aware of their shared early-2000 patent awards for nanoscale semiconductor lasers and such.
As far as my searching DDhawk, what I have seen on the board of your DD and what hint of broad understanding show in your posts, following your routine practices would be a step up for my game.
Here is a 23 minute youtube of 'our girl' Jennifer from Feb 2014. If the dots she is using aren't from one of them QTMM non-disclosures I'm miffed.
Large area luminescent solar concentrators use Giant-shell QD
ih8aloss, I did see that tetrapod research abstract. This abstract is very similar to chessmite post#25298 link about Luminescent Solar Concentrators (LSC). Here they claim a 100-fold increase in LSC efficiency utilizing the giant shell QDs.
Session 6. Quantum dots devices and applications (I)
Large area luminescent solar concentrators based on “Stokes-shift-engineered” nanocrystals in mass polymerized PMMA matrix
Francesco Meinardi1*, Annalisa Colombo1, Kirill A Velizhanin2, Roberto Simonutti1, Monica Lorenzon1, Luca Beverina1, Ranjani Viswanatha3, Victor I Klimov4* and Sergio Brovelli1*
Luminescent solar concentrators (LSCs) are cost-effective complements to semiconductor photovoltaics (PV) that can boost the output of solar cells and allow for integration of PV-active architectural elements into buildings (i.e. PV windows). Colloidal quantum dots (QDs) are attractive for LSCs but their small Stokes-shift results in re-absorption losses that hinder the realization of large-area devices. Here we use "Stokes-shift-engineered" CdSe/CdS QDs with giant shells (giant-QDs) to realize LSCs without reabsorption losses for device dimensions up to tens of centimeters. Monte-Carlo simulations show 100-
fold increase in LSC efficiency using giant-QD with respect to core-only QDs. We demonstrate the feasibility of this approach by using high-optical-quality QD-polymethylmethacrylate (PMMA) nanocomposites fabricated by a modified industrial method that allows to preserve the light-emitting properties of giant-QDs upon incorporation into PMMA. The study of these LSCs yield optical efficiencies >10% and demonstrate a significant promise of Stokes-shift-engineered QDs for large-area LSCs fabricated via industrial methods.
I chanced on this related article about Viktor Klimov's LSC work. http://www.futuretimeline.net/blog/2014/04/21.htm#.U5N1mNJDvm4
I imagine the article made it to this board at its publish back in April 2014 but I'll link it since the photo of Quantum dot LSC devices is identical to the one in Klimov's abstract above.
Hollingsworth and Mikhailovski receive LANL nanoscale semiconductor award
The two are pictured here in the top left corner, https://www.google.com/search?hl=en&site=imghp&tbm=isch&source=hp&biw=1807&bih=945&q=%22Jennifer+Hollingsworth%22+%22Alexandre+Mikhailovski%22&oq=%22Jennifer+Hollingsworth%22+%22Alexandre+Mikhailovski%22&gs_l=img.12...1521.18569.0.20111.11.9.0.2.0.0.165.826.8j1.9.0....0...1ac.1j2.45.img..11.0.0.CDNlNgupczI#hl=en&q=%22Jennifer+Hollingsworth%22+%22Alexandre+Mikhailovski%22&tbm=isch
"The team of Jennifer Hollingsworth and Alexandre Mikhailovski received the Distinguished Postdoctoral Performance award for its work in the area of synthetic chemistry of nanoscale semiconductor particles and work on optical characteri-zation of those nanoparticles using spectroscopic methods, including ultrafast and near-field optical spectroscopies." is quote from a cached copy here describing their April 2014 award,
http://webcache.googleusercontent.com/search?q=cache:http://pearl1.lanl.gov/external/Research/postdocs.htm
I can't open a thing at LANL for days. Took a while to determine this was not the same Hollingsworth news as yours DDhawk. Maybe LANL is holding off an internet attack by the Chinese or one of our allys trying to save on R&D. Or maybe its me trying to access content on a US server. (sniff, sniff)
Swamp Angel asked "Does the report say who won the QTTM prize that was to be awarded at that conference?"
Which student or postdoc received the prize is not named in the conference abstracts document.
This conference website link, http://www.qd2014.it/pagina.aspx?pagina=16 describes the "QD2014 Tetrapod Award" sponsored by Quantum Materials Corporation.
chessmite post #20874 from 01/01/14 is about the 'then' monthes away conference and the Tetrapod Award. It seems they've changed the portion 'quantumdots2014.com' of his weblink to 'qd2014.it'. I did not have a clue what Tetrapod award your were speaking of Swamp Angel. I was neither shareholder at QTMM or reading this board 01/01/2014.
The report you reference has 3 to 5 abstracts for each of the 20 sessions held over the 5 days of conference.
Session 1. Quantum dots in Silicon – Optical properties
Session 2. Wave-photon interaction in quantum dots
Session 3. Epitaxial Growth of quantum structures
Session 4. Photophysics of colloidal quantum dots (I)
Session 5. Magneto optics (I)
Session 6. Quantum dots devices and applications (I)
Session 7. Single photon generation in quantum dots
Session 8. Electrical & Transport Properties in quantum dots
Session 9. Spin Dynamics in quantum structures (I)
Session 10. Quantum Logic
Session 11. Magneto Optics (II)
Session 12. Photophysics of colloidal quantum dots (II)
Session 13. Photonics (I)
Session 14. Quantum dots devices and applications (II)
Session 15. Quantum dots in Silicon – Electrical properties
Session 16. Photon entanglement
Session 17. Auger processes
Session 18. Coupled Quantum Dots
Session 19. Spin Dynamics in quantum structures (II)
Session 20. Photonics (II)
I tried searching the document for medical related subjects like those in DDHawks recent links. No obvious matches.
This one, "CTAB Modified Quantum Dots-Based Specific Metal Sensing" caught my eye. Seems they are trying to improve QD sensitivity detecting copper overload related to Alzheimers and other neurodegnerative diseases. An excerpt:
"..., copper is an essential trace element in various biological processes. However, it may exhibits high toxicity and can cause damage to central nervous system and disorders associated with neurodegenerative diseases (e.g., Wilson’s diseases and Alzheimer’s disease)[1] under overloading conditions. Thus, the identification and measurement of copper ions (Cu2+) in environmental matrix and biological fluids has become increasingly important and been highly demanded. Semiconductor quantum dots (QDs) with high fluorescent quantum yield, intense and stable fluorescent properties are gained more and more research interests, and it can offer significant advantages and exhibit highest sensitivity in QD-based ion sensors for applications in biology, pharmacology, and environmental science. [2] We indicate a QDs-based specific metal sensing method for Cu2+ detection in water. CTAB modified CdSe/ZnS QDs is used as a fluorescent probe. ..."
8th International Conference on Quantum Dots, May 2014, Pisa, Italy
This 440 page document seems a slow download. Abstracts for presentations made in the 20 sessions over the conferences 5 days are here. LANL's Viktor I. Klimov was an Invited speaker.
http://www.qd2014.it/upFile/QD2014%20Books%20of%20Abstract%20Final/QD2014-Book%20of%20Abstracts_COMPLETE.pdf
Last quarterly report SGLB announced ending their consulting services. The companys forward strategy is industry exposure and adoption of PrintRite and SGLB's higher headcount nowadays work toward that end. Those balance sheet bolstering consulting revenues go to zero through the next quarter or two.
Share price should typically trend lower as those consulting revenues portion of assets are no longer realized and shareholders determine their fair prices.
Definition of 'SEC Form NT 10-Q'
http://www.investopedia.com/terms/s/sec-form-nt-10-q.asp
QTMM to attend Smithers QD and Phosphors Conference
https://www.smithersapex.com/quantum-dots-forum-2014.aspx
The recent Thick-Shell Quantum Dot Technology Express Licensing announcement refers to LANL's Dr. Jennifer Hollingsworth, their Principal Investigator for Thick-Shell Quantum Dots at Center for Integrated Technologies (CINT).
She is also 'first listed inventor' on that Thick-shell nanocrystal quantum dots patent http://www.google.com/patents/US7935419 LANL controls.
This link is a CINT professional bio for her, credits her over 3000 citations and 63 publications since 1998 with many quantum dot subjects. http://www.cint.lanl.gov/docs/jennifer_hollingsworth_cv.pdf
Todays "Moving Closer to Volume Production" presser included "QMC is now proud to announce that they have teamed with LANL and have jointly written and submitted a proposal for funding to the recent DOE EERE Funding Opportunity for Solid-State Lighting Advanced Technology R&D"
Googling "DOE" "EERE" and "Jennifer Hollingsworth" multiple workshop and roundtable documents appeared showing Dr. Hollingsworth has been participating in Solid-State Lighting initiatives yearly this decade. Might bode well for a submitted proposal.
Doderer, Squires, Ghassan and Benjamin convert salary accrued into options:
Four Form 4's since the market open and no comment on the board surprises me. Gentlemen?
Derivative Security Price $.04
Exercise Price $.06
Exercise Date 2/14/2014, Expiration Date 2/14/2019
10,312,500 Common Stock Purchase Options between the 4. Mr. Squires the only 10% or greater owner among them.
Makes sense to see it now. Wish there had been an 'official mention' what the output will be of the new production apparatus the recent announced funding brings.
Tania Betancourt was pictured with Mr. Squires at the Star Park. Tried scratchin bout a bit for her interests and expertise. http://www.researchgate.net/researcher/12466834_Tania_Betancourt/ lists 7 publications in the 2006-09 timeframe. Earlier work in the same vein was this, "Targetable biodegradable nanoparticles for delivery of chemotherapeutic and imaging agents to ovarian cancer" By 1981- Tania Betancourt.
Tania also had a couple SBIR mentions with HHS ties with an Innosense, LLC.
lmmunonanoparticle Optical Sensor for CTC Detection,N43CO201000050,HHS,HHS,SBIR,2010,1,200000.00,"Innosense, LLC",2531 West 237th Street,,Torrace,CA,90505-5245,No,No,No,,,(310) 530-2011,kisholoy.goswami@innosense.us,Tania Betancourt
Enzyme-activated Nanoparticles as Contrast Agents for Optical Detection of Cancer,1R43CA144129-01,HHS,HHS,SBIR,2010,1,183896.00,"Innosense, LLC",2531 West 237th Street,,Torrace,CA,90505-5245,No,No,No,Kisholoy Goswami,,,kisholoy.goswami@innosense.us,Tania Betancourt,,3105302011,TANIA.BETANCOURT-1@INNOSENSE.US
Perhaps the tetrapod Q-Dot lends itself to some of the technologies Dr. Betancourts work has focused on, also explored at Innosense. http://www.innosense.us/technologies.html
Appreciate all the good QD info shared here. Has helped me begin an understanding.
UCSB Eric McFarland takes DOW Chair at UniversityOfQueensland
http://www.uq.edu.au/uqcontact/index.html?page=205044&pid=195705
"To be known as The Dow Chair in Sustainable Engineering, McFarland will commence the five-year post in the first quarter of 2014. As inaugural director, he will drive UQ research and education into some of the world’s most pressing sustainability challenges, such as the need for cleaner energy, clean water and conservation."
HYSR presser Jan 2014 about UCSB research extension through July 2014 named Syed Mubeen Jawahar Hussaini Ph.D. leading that investigation.
Dr. Hussaini joined HYSR June 5, 2013.
rustydog62
Appreciated your link for "SQUID-based ULF MRI and Superparamagnetic Relaxometry for Early Cancer Diagnostics"
Got me looking and I found this paper, "SQUID Instrumentation for Early Cancer Diagnostics: Combining SQUID-Based Ultra-Low Field MRI and Superparamagnetic Relaxometry", http://www.osti.gov/scitech/servlets/purl/1094826
by those same LANL Applied Modern Physics Group scientists credited in your linked paper. This linked paper was presented at the International Superconducting Electronics Conference, held 7-7-2013 in Cambridge, Mass.
Text within includes, "In this presentation we use the most recent publications from Dr. Edward R. Flynn group". Dr. Flynn's research referenced several places and Senior Scientific, LLC is named twice.
In your article, under Acknowledgment it reads, "The authors also thank Petr Volegov for his data analysis tools that were invaluable in the creation of the algorithms for this work."
This dated 2011 article titled, "Atomic magnetometers used to make ultra-low field MRI", http://www.domain-b.com/technology/Health_Medicine/20111111_magnetometers_2.html
is about non-cryogenic anatomical imaging efforts by LANL Applied Modern Physics group. Those named in the work are many of these same authoring scientists, algorithmist Petr Volegov and one of Senior Scientifics recently added researchers, Todor Karaulanov.
Néel relaxation- Magnetic Nanoparticles for Cancer Gene Therapy
Greetings All. Have not followed the board very long so sorry if either are reposts.
Molecular Imaging of HER2-Targeted Superparamagnetic Nanoparticles in an Orthotopic Mouse Mammary Tumor Model by Nanomagnetic Relaxometry http://www.wmis.org/abstracts/2013/data/papers/P253.htm
is from a Sept 2013 presentation by Dr. E.R.Flynn and S. Miller at the World Molecular Imaging Society.
Development of Magnetic Nanoparticles for Cancer Gene Therapy: A Comprehensive Review
http://www.hindawi.com/isrn/nanomaterials/2013/646284/
Quite a bit about Superparamagnetic Iron Oxide Nanoparticles and magnetic cancer theragnosis.
Looking round the web seems Leyma P De Haro has been involved with leukemia research at University of New Mexico. I have read other posters comment Senior Scientific "abruptly" curtailed their leukemia involvements. Can anyone enlighten me?
uksausage,
If you go back through SGLB filings there have been other automotive supplier collaboration announcements. Each ended with, "There is no assurance that the parties will be able to enter into the definitive agreements on the terms proposed, or on any other terms" qualifier.
Burke E. Porter has as large a global presence as any of those 'once announced' potential automotive partners which I looked at further. And the new Director Tom O'Marra has a deep automotive experience.
That said, 3D metal parts for automotive is less practical than 3D metal for aerospace because of the potential run-rates involved and time req'd to print metal. The GE collaboration means to speed up the process as was the stated goal of the 2-year Honeywell-Morris-Sigma DARPA. (I wonder if that was kept alive when GE bought Morris?).
DOD, DARPA, NAMII, NIST are all working to move this additive science forward and faster 3D metal print is key. SGLB is gonna toss a hat in that ring.
Kataeb777
10-Q states, "and sales of two of our PrintRite3D systems to a leading aerospace company for use for test and evaluation purposes with respect to 3D metal printing".
Probably GE referenced there and commercialization would result from meeting GE test and evaluation criteria. Don't know what you expect of Sigma at the moment.
uksausage,
Dr. Davé has a technical consulting service of his own named Northern New Hampshire Technical Associates you can see at this web address:
http://www.nnhtech.com/about-us.html
DARPA Honeywell Contract HR0011-12-C-0037 w/SGLB IPQA w/Morris
http://www.midwestsampe.org/content/files/events/dpmworkshop2012/Neumann%20Rapid%20Low%20Cost%20AM.pdf
Below is the Open Manufacturing, Solicitation Number: DARPA-BAA-11-54 You can open/save a .pdf there describing DARPA Open Manufacturing program.
https://www.fbo.gov/index?s=opportunity&mode=form&id=be4346eff31b9a86d1b5ab8ebfe710af&tab=
Placement price discount to closing average last trading, etc, etc
You are right SeanBoy. It is usual and customary.
There may still be millions of shares SGLB 'payed for services rendered' out there in the sub .02 range.
And consider Udo and the Patagonia fellow. They are both entered into agreements receiving sub .03 shares for ongoing obligations providing SGLB services.
As an investor/s, going to stake $1.2 million in SGLB, would you see a premium accepting shares for your 'hard cash' investment priced 2 or 3 times the value of SGLB shares going to Udo or Patagonia? When the use of your cash means reason to keep their agreements in effect.
Maybe the May 2013 JTDA with GE 'looked very real' as the investors were approached, but same source recurring revenues are not on the books yet.
The whip-saw price action following that publicity goose to +.10 is exactly why the $1.2 million investor/s locked their premium in the way they did. jmo
Appreciate your opinions and substantive posts bankshot.
Have a good weekend.